

# MUGEN

 [consortiapedia.fastercures.org/consortia/mugen/](http://consortiapedia.fastercures.org/consortia/mugen/)

## Research Areas



### Tool Development

Innovation



### Biomarker Research

Diagnostic



### Basic Research



### Data-Sharing Enabler



### Product Development

Data

## At a Glance

- Status: **Completed Consortium**
- Year Launched: **2005**
- Initiating Organization: **European Commission 6th Research Framework Programme**
- Initiator Type: **Government**
- Location: **Europe**

## Abstract

MUGEN aims to structure and shape a world-class network of European scientific and technological excellence in the field of 'murine models of human immunological disease', to advance understanding of the genetic basis of disease and to enhance innovation and translatability of research efforts. MUGEN is focusing on further supporting already established capabilities, through greater integration of already set up services as well as investment on the development of new technological cores, expanding and enriching its research efforts and diversifying its dissemination initiatives to raise awareness.

## Mission

MUGEN's specific mission is to bring together different expertise from academic and industrial

laboratories in order to study human immunological disease by integrating the participant's strengths in immunological knowledge with new approaches in functional genomics. In this way, MUGEN expects to bring Europe a competitive advantage in the development of new diagnostic and therapeutic tools. In concert, MUGEN promotes training of young researchers and exploitation, dissemination, and communication of scientific and technological excellence both within and outside of the network, to include all interested stakeholders in the area of human immunological diseases.

---

## Consortium History

For links to MUGEN research articles, click [here](#)

---

## Structure & Governance

The Project Governing Board (PGB) is (initially) composed of the six members that historically formed the Steering Committee for conceptualizing and materializing the proposal for the MUGEN Network of Excellence (NoE). The Coordinator acts as the chairman of the PGB for the full duration of the Network, whereas the Ethics Advisor and the Commission's Scientific Officer are entitled to attend PGB meetings as non-voting observers. The PGB performs both executive and administrative functions, among which are formulating and revising the strategic priorities of the Network, evaluating, approving, and adopting the Joint Programme of Activities (JPA) and reviewing and approving all Network reports and deliverables.

---

## Financing

MUGEN is a project funded under the European Commission's 6th Research Framework Programme.

---

## Intellectual Property

MUGEN participants will share information and technology platforms and will develop a coordinated agenda of scientific events in order to communicate their scientific achievements to a wider scientific audience, as well as to the general public.

## Impact/Accomplishment

---

To view a list of MUGEN's network news, click [here](#)

## Links/Social Media Feed

---

Homepage <http://www.mugen-noe.org/index-2.html>

## Points of Contact

---

To contact MUGEN, follow this [link](#)

## Sponsors & Partners

---

Biomedical Sciences Research Center "Al. Fleming"

Inserm EMI -0101- Institut Pasteur

Deutsches Krebsforschungszentrum

Centre d' Immunology de Marseille – Luminy

University of Milano – Bicocca

Inst. Of Experimental Immunology, University of Zurich

Helmholtz-Zentrum für Infektionsforschung

The Netherlands Cancer Institute

EMBL

Medical Research Council

Medical Inflammation Research  
Genopolis Functional Genomics Consortium  
Institute for Research in Biomedicine  
Istituto di Ricerche Farmacologiche Mario Negri (withdrawn) until 31/8/2005  
Heinrich- Heine- Universitat D?sseldorf  
Deutsches Rheuma – Forschungszentrum  
Istituto di Biologia Cellulare  
University of Lausanne  
Center for Blood Research  
Biovista  
Innate Pharma

Cytos Biotechnology AG  
Arexis AB (withdrawn)  
Bank Invest- group  
Istituto Clinico Humanitas since 1/9/2005  
Biovitrum AB (withdrawn)  
University of Cologne  
BioMedCode  
Karolinska Institute  
University Medical Center Groningen

---

Updated: **06/20/2017**